Lung Cancer News

 
 
  • Coping Strategies Used by Dying Cancer Patients Affect QOL Patients with incurable cancer use a variety of coping methods, and although some may improve quality of life and mood, others have a detrimental effect.
  • Lichenoid Features Tied to Cancer Immunotherapy Skin Problems Skin eruptions in cancer patients due to use of antagonist antibodies to programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) show lichenoid features on histologic analysis, according to a small case series.
  • 1 in 12 Chance of Second Cancer in Many Survivors Cancer survivors are always at risk for a second primary cancer. A new study provides details, including that bladder cancer survivors are at most risk.
  • Upfront Immunotherapy for Lung Cancer? Not Yet Two new immunotherapies are approved for use in patients who progress while receiving standard chemotherapy. Is it time to use these drugs first, before or with chemotherapy?
  • Statin Treatment Linked to Fewer Cancer Deaths Being treated for high cholesterol with statins is being linked with a reduced risk of death and better survival from four common cancers, a medical conference has heard.
  • UK Cost Agency Rejects Bristol's Opdivo for Kidney Cancer Bristol-Myers Squibb's immunotherapy drug Opdivo (nivolumab) is not worth using on the state health service for treating kidney cancer, Britain's healthcare cost-effectiveness watchdog said on Tuesday.
  • Attack Inflammation to Boost Quality of Life in Advanced Cancer Patients A new study ties systemic inflammation to reduced quality of life, independent of performance status, in patients with advanced cancer, suggesting that efforts to reduce systemic inflammation are warranted, the researchers say.
  • 'Liquid Biopsy' for Lung Cancer May Help Avoid Invasive Testing Plasma genotyping may help some advanced non-small-cell lung cancer (NSCLC) patients who are candidates for treatment with osimertinib avoid tumor biopsies, new findings show.
  • SCCT Possible Cancer Finding on Pre-TAVR CT Doesn't Affect Survival "The presence of malignancy may not necessarily be a contraindication to TAVR, since the life-limiting condition may be the aortic stenosis," said one expert.
  • ASCO Oncologists Discuss Bestseller: When Breath Becomes Air At a special session during the recent ASCO meeting, oncologists got a chance to ask questions about the neurosurgeon author of the bestselling book who died from lung cancer at age 37.
  • ASCO Finally, RCT Results for Proton Therapy in a Cancer Results from the first randomized controlled trial of proton therapy indicate that the new technology is no better than IMRT in the treatment of lung cancer.
  • One in Four Patients With Advanced NSCLC Goes Untreated Twenty-seven percent of patients with advanced non-small cell lung cancer (NSCLC) receive no treatment, new findings show.
  • Merck's Keytruda Prolongs Life in Big Lung-Cancer Study Patients with untreated advanced non-small cell lung cancer who took Merck & Co's Keytruda (pembrolizumab) in a large trial went longer without their disease worsening and showed a survival advantage over those given standard chemotherapy, the drugmaker said on Thursday.
  • SNMMI PET/CT Sharpens Lung Cancer Staging, Prognosis The simple imaging method could improve the staging of non-small-cell lung cancer, and the additional information on overall tumor burden could help guide clinical decision-making.
  • Knowledge About LDCT Lung Cancer Screening Low A small survey of South Carolina family physicians found reluctance in referring high-risk patients for LDCT screening despite multiple professional organizations' recommendations.
  • Excess Cancer Risk With Primary Immunodeficiency Diseases Patients with primary immunodeficiency diseases (PIDD) have an excess incidence of cancer, principally lymphoma, according to research presented at the American Society of Clinical Oncology annual meeting.
  • Breath Analysis Normalizes After Lung Cancer Resection The levels of exhaled carbonyl compounds decrease to normal after lung cancer resection, researchers report.
  • ASCO Web App Ups Lung Cancer Survival by 7 Months In a phase 3 randomized clinical trial, cancer care enhanced by a web application improved overall survival by 7 months over standard care.
  • ASCO Largest Liquid Biopsy Study: Compares With Tissue Sampling 'Oncologists are excited about ctDNA analysis, although further refinement of these techniques is required,' said Rafael Rosell, MD.
  • Genentech, OSI to Pay $67 mln Over Drug Claims Pharmaceutical companies Genentech and OSI Pharmaceuticals LLC will pay $67 million to resolve allegations they made misleading statements about the effectiveness of lung cancer drug Tarceva (erlotinib), the U.S. Justice Department said on Monday.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.